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Editorial
On the Road to an Impact Factor for eCAM
Edwin L. Cooper
Laboratory of Comparative Neuroimmunology, Department of Neurobiology, David Geffen School of Medicine
at UCLA, University of California at Los Angeles, Los Angeles, CA 90095-1763, USA
Last year 2006 was indeed a fruitful year from many
points of view and, mostly with respect to eCAM,
attempts were made to broaden the scope of influence
and to focus on what I deemed regions of eCAM
strength. To that end, I spent nearly three months at the
Institute for Advanced Studies, University of Bologna
with Prof. Claudio Franceschi as my host—a convenient
launching point that allowed interaction with eight other
members of the Editorial Board in northern Italy (1).
Another area that received some attention was the
National Research Center, Dokki, Cairo, Egypt, where
there is a wealth of activity especially using products
from plants and animals. The Antiaging Meeting in
Vienna was particularly enlightening and as with all
meetings, my focus was on speaking the virtues of eCAM
and thereby recruiting high-level papers. Why was the
Vienna meeting unique? In contrast to other CAM/
integrative conferences I have attended, the exhibitors
and speakers did not center on chronic diseases but
rather on a more esthetic, non-healing approach to
antiaging.
Another area of high activity was witnessed at the 2nd
World Congress of Ayurvedic Medicine held in Pune
India. I was invited to give a Writer’s Workshop along
with eCAM Editorial Board member, Dr Alex Hankey.
After three intensive lectures on the philosophy behind
eCAM and the mechanisms of publishing in it, I then
worked several hours with individuals who brought in
manuscripts of varying lengths and quality of writing
and presentation of results. Some were ready to be peer
reviewed, whereas others required substantial revisions
essential for a high-quality manuscript. It was my job
to view them critically and to advise on the best strategy
for publishing in eCAM. The impact and enthusiasm
in India was enormous and overwhelming. As a result,
we have appointed seven new members to the Editorial
Board.
Moving from India to Japan, we had very good and
promising news at the eCAM family meeting. I call this
our annual gathering of OUP from Japan with Patty
Willis, and Prof. Nobuo Yamaguchi. We look seriously
at the past year, problems, triumphs and where we go
next. We listened to several reports from Akiko Tanaka
(Commissioning Editor), Miki Matoba (Deputy Director)
and Dr Toyoshi Onji (Journals Director). Indeed this
meeting was most pleasant, productive and extremely
upbeat from several points of view. First, there was the
report of an astronomical burst of submissions at
midyear. Second, we are increasing the rejection rate in
order to improve quality. Third, we see an increase in
more clinical papers. Fourth and most importantly, there
are hopeful predictions of the long-awaited impact factor,
that elusive number which seems to guide authors in their
choice of where to submit manuscripts. Traveling the
world, I even hear stories of universities that reward their
faculty monetarily for publications in the high impact
factor journals. Yet, seeing ‘impact factor’ from the other
side of receiving manuscripts, my decades in science and
the world of publishing urge prudence. Just as politicians
lose their integrity by making decisions solely based on
polling their constituencies, eCAM must continue to
choose articles based on their intrinsic worth rather than
their ability to attract references. In six or seven months,
we will see if those directions have serendipitously shared
common ground.
According to Toyosho Onji, eCAM appears to be
‘nicely chaotic’! Contrary to what may appear at first
glance to be derogatory, my vision of eCAM’s publica-
tions appears just as Onji puts it, as chaotic, but nicely!
Chaotic of course is a word form of chaos. So what does
it mean and imply for the appearance, inclusions and
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properly cited.thrusts in eCAM? Chaos means disorder and its
synonyms are: confusion, bedlam, anarchy, pandemonium,
commotion, disarray, turmoil, madness, mess and unruli-
ness! Of course the antonym for this is order, which
means neat, tidy, just to name a couple of similar
meanings. Now we ask the question, is there a sense of
order to eCAM?O ri seCAM nicely chaotic?
By any way that we may interpret Onji’s compliment in
using the word chaotic, the vision for eCAM and what
we have done in its publications, eCAM encompasses
some of the meanings of chaos. In the common lexicon of
CAM, one of eCAM’s efforts would hardly conjure
bioprospecting, to use an oft-quoted example, yet this has
been a major thrust for eCAM. In a few words, this
course has been an attempt to redirect the invertebrate
immunologist’s past understanding of the invertebrate’s
immune system for its own sake (2–7) into the scope of
CAM. This research focus has led to harnessing the
antimicrobial peptides that invertebrates synthesize and
secrete after challenge with antigens, some of which may
be pathogenic, as new wave antibiotics or anticancer
therapies. After all, invertebrates must be doing some-
thing right to have survived longer than most other
animals including humans without pharmaceutically
engineered CAM products. As we look to these animals
whose survival speaks of their strength, we also
encourage true scientific investigation into the crudely
defined concoctions that have aided the ill in ancient
cultures for thousands of years and survived in tradi-
tional medicines all over the world.
The vision for eCAM is to take those concoctions and
apply to them the rigorous standards of evidence base
and to unravel the sometimes-confusing scheme of CAM
qua TCM, Ayurveda, Kampo, Unani, etc. Of course, if
we follow the rules and regulations of what is laid down
by the ancient healers of these practices, there are
acceptable definitions as to what the components will
do to alleviate symptoms. The problem is how to
translate those ancient formulas into intelligible language
amenable to the rigors of evidence-based analyses.
Moreover, there is the inherent and obvious need to be
certain that there is equivalence of the current biomedical
terminology to its western allopathic definition. That is
precisely the point. Start with the early principles of
TCM, Ayurveda, Kampo and then subject these ancient
disciplines and practices to rigorous analysis and an
experimental strategy that uses the prevailing biomedical
approach to human illness. Of course, the peak of a
pyramid glows with the epitome, the gold standard,
randomized clinical trials. As difficult as such an approach
may seem, this strategy can be approached and partial
answers sought through the utility of in vitro applications
and results from the analyses using a multitude of available
and relevant animal models. After all, humans are related
to the so-called lowly animals (some of which we revile,
eat, spray with insecticides, etc.).
Finishing volume 3, 2006 has been momentous. The
last three years of one decade in my life were also
completed ushering in for 2007 another decade and
volume 4. Some members of the Editorial Board were
present at my momentous birthday December 23 and
were here to celebrate: our graduate student member
Shinji Kasahara (University of Washington). Aristo
Vojdani, Mepur Ravindranath, Michel Tournaire and
one non-member speaker from the Kanazawa
Symposium, Arnie Loel. Other poignant messages were
sent from Editorial Board members outside: Francesco
Marotta, Andrea Cossarizza, Philippe Roch, Haruhisa
Wago and Taras Usichenko. The celebration even began
early in November in Kanazawa Japan with a dinner
hosted by our indefatigable Founding Managing Editor,
Prof. Nobuo Yamaguchi, naturally accompanied by
abundant Beaujolais nouveau, which always seems to
arrive with our coincident OUP family meeting. Of
course, I cannot forget to offer special mention of
champagne and my December flower narcissus, so
generously sent in absentia by dear friend and eCAM
colleague Patty Willis.
Chaos perhaps not, but diversity yes, witness every
issue of eCAM from its inception through volume 3. We
have emphasized biological approaches to CAM. After
all, dealing with human problems is about life and should
be inclusive of all life. That is what eCAM is about—life
and knowing how it works at all levels will help us
discover how to fix problems.
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